BioIVT Blog

    Biomarkers in Urine

    By Heather Manza Mar 29, 2018
    In 1938, it was discovered that the urine of a woman could be injected into frogs as a way to test for pregnancy (1). If the frogs laid eggs after the injection, then the woman was pregnant. The assay had a relatively quick turn-around time, was simple, and generally accurate…the principle being that the hCG hormone excreted in urine of pregnant women caused the frogs to lay eggs. However, as always, there was a better way. Read More >

    Has Major Cancer Gene Met Its Match?

    By Samantha Bussell Nov 18, 2017
    When working on targeted therapeutic drug development in oncology, tumor mutation heterogeneity makes it difficult to treat all patients. However, there is one biomarker that has been found to affect 30% of all tumor cases- the RAS mutation. The abundance of this genomic abnormality was discovered via the ongoing investigations into targeted RAS cancer therapies. Researchers thus have been working to find a method to block the RAS pathway in all tumors, with the desired outcome to treat all patients regardless of differing cancer subtype. Read More >

    CTE & ALS at the Forefront at the Powering Precision Health Summit

    By Courtney Noah Oct 26, 2017
    I just came back from an educational and inspirational two days attending the Powering Precision Health Summit held in Boston, MA. Breakout sessions throughout the meeting focused on targeted therapies and biomarker detection for neurodegenerative, oncology, autoimmunity, cardiovascular and metabolism diseases. Read More >

    A Predictive Model for Drug Response?

    By Samantha Bussell Mar 03, 2017
    With an incident rate of 55,000 diagnosed cases per year, thyroid cancer is becoming the fastest-growing cancer type in the United States. Like other tumor classifications, genetic abnormalities and mutations play a key role in the proliferation of cancer cells; and although previously identified point mutations are observed in 90% of thyroid cancers, driver mutation intricacies have an opportunity for exploration. For example, the insulin-like growth factor 2 mRNA-binding protein 3’s (IGF2BP3) activation is still not fully understood. Read More >

    The Telomere: Does Length Impact Cancer Related Genomic Alterations?

    By Samantha Bussell Feb 10, 2017
    Telomeres are regions of highly repetitive DNA at the end of a chromosome that assists in cellular duplication and rejuvenation. This physiological function has been historically associated with biological aging as the length of the telomere shortens after division and subsequently alters the effectiveness of DNA replication. However, a team of researchers at the Jackson Laboratory at the University of Texas MD Anderson Cancer Center (UTMD) have found that the length is also impactful in genetic alterations in 31 different types of metastatic tumors. Read More >

    Research and Discovery Process in Drug Development

    By Lauren Vagnone Nov 15, 2016
    BioIVT understands the importance of the R&D process, as there are multiple methods that can be leveraged from concept initiation to drug delivery. In an effort to assist in the advancement in personalized medicine we would like to break down the different validation methods that can be leveraged in offering patients faster diagnoses, fewer side effects, and better outcome prior to initiating pre-clinical trials. Read More >

    Tissue Variety in Breast Cancer Research

    By Samantha Bussell Sep 08, 2016
    Resistance to estrogen-deprivation therapy is common in ER+ breast cancer tissue. To better understand this evolution to resistance, genomic characterization of multiple primary tumors is imperative for comprehensive results and identifying therapeutic targets ( For researchers, attaining samples that have been confirmed for diagnosis and receptor expression supports the inherent need for accuracy in tissue characterization. Read More >


    Enter your email to sign up today!